Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against .
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsSanchez Alberti, Andrés
Bivona, Augusto E
Matos, Marina N
Cardoso, Alejandro C
Cazorla, Silvia I
Guzmán, Carlos A
Malchiodi, Emilio L
MetadataShow full item record
AbstractThere are several unmet needs in modern immunology. Among them, vaccines against parasitic diseases and chronic infections lead. Trypanosoma cruzi, the causative agent of Chagas disease, is an excellent example of a silent parasitic invasion that affects millions of people worldwide due to its progression into the symptomatic chronic phase of infection. In search for novel vaccine candidates, we have previously introduced Traspain, an engineered trivalent immunogen that was designed to address some of the known mechanisms of T. cruzi immune evasion. Here, we analyzed its performance in different DNA prime/protein boost protocols and characterized the systemic immune response associated with diverse levels of protection. Formulations that include a STING agonist, like c-di-AMP in the boost doses, were able to prime a Th1/Th17 immune response. Moreover, comparison between them showed that vaccines that were able to prime polyfunctional cell-mediated immunity at the CD4 and CD8 compartment enhanced protection levels in the murine model. These findings contribute to a better knowledge of the desired vaccine-elicited immunity against T. cruzi and promote the definition of a vaccine correlate of protection against the infection.
CitationFront Immunol. 2020 Feb 21;11:128. doi: 10.3389/fimmu.2020.00128. eCollection 2020.
AffiliationHZI, Helmholtz Zentrum für Infektionsforschung GmbH, Inhoffenstr.7, 38124 Braunschweig, Germany.
JournalFrontiers in immunology
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International
- Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.
- Authors: de Alencar BC, Persechini PM, Haolla FA, de Oliveira G, Silverio JC, Lannes-Vieira J, Machado AV, Gazzinelli RT, Bruna-Romero O, Rodrigues MM
- Issue date: 2009 Oct
- Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
- Authors: Bivona AE, Sánchez Alberti A, Matos MN, Cerny N, Cardoso AC, Morales C, González G, Cazorla SI, Malchiodi EL
- Issue date: 2018 Mar
- TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice.
- Authors: Hegazy-Hassan W, Zepeda-Escobar JA, Ochoa-García L, Contreras-Ortíz JME, Tenorio-Borroto E, Barbabosa-Pliego A, Aparicio-Burgos JE, Oros-Pantoja R, Rivas-Santiago B, Díaz-Albiter H, Garg NJ, Vázquez-Chagoyán JC
- Issue date: 2019 Jan 7
- TcG2/TcG4 DNA Vaccine Induces Th1 Immunity Against Acute Trypanosoma cruzi Infection: Adjuvant and Antigenic Effects of Heterologous T. rangeli Booster Immunization.
- Authors: Gupta S, Salgado-Jiménez B, Lokugamage N, Vázquez-Chagoyán JC, Garg NJ
- Issue date: 2019
- Experimental Nanovaccine Offers Protection Against Repeat Exposures to Trypanosoma cruzi Through Activation of Polyfunctional T Cell Response.
- Authors: Chowdhury IH, Lokugamage N, Garg NJ
- Issue date: 2020